Multi‐Omics Analysis of TYMS as a Prognostic Biomarker and Therapeutic Target for Lung Adenocarcinoma
Cancer Medicine · 2026-04 · 15 (4)
DOI: 10.1002/cam4.71814 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 19.04.2026. Verfasst von Hansen Shi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory Medicine Center, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong, People's Republic of China. Hauptthemen laut MEDLINE: Thymidylate Synthase, Biomarkers, Tumor, Lung Neoplasms, Adenocarcinoma of Lung. Die Arbeit nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Guangdong Basic and Applied Basic Research Foundation, Start-up Fund for High-level Talents in Affiliated Hospital of Guangdong Medical University, Medical Science and Technology Research Project of Guangdong Province.
Abstract (Originalsprache)
Lung adenocarcinoma (LUAD) is a predominant form of lung cancer with poor prognosis due to early diagnosis challenges and treatment resistance. Thymidylate synthetase (TYMS), a key enzyme in DNA synthesis, has been associated with poor prognosis in multiple cancers, yet its multi‐omics characteristics in LUAD remain systematically uncharacterized. This study focuses specifically on LUAD, integrating transcriptomic, proteomic, and genomic data to elucidate TYMS expression patterns, prognostic value, immune microenvironment interactions, and therapeutic potential. Using data from The Cancer Genome Atlas (TCGA), the Clinical Proteomic Tumour Analysis Consortium (CPTAC), the Genome‐Tissue Expression Project (GTEx), the Gene Expression Profile Interaction Analysis (GEPIA2), etc., we conducted comprehensive bioinformatics analyses of TYMS in LUAD. TYMS showed significant overexpression at both mRNA and protein levels in LUAD tissue. High TYMS expression correlated with earlier tumour staging, higher histological grade, and poor prognosis. Functional enrichment analysis revealed TYMS involvement in p53/Rb and mammalian Target of Rapamycin (mTOR) signalling pathways. TYMS expression was associated with immune cell infiltration, showing negative correlation with B‐cell activity and positive correlation with neutrophil infiltration, as well as significant association with Cytotoxic T Lymphocyte‐Associated Protein 4 (CTLA4), Programmed Death‐1 (PDCD1, PD‐1), and Interleukin‐6 (IL‐6). Somatic copy number variation (SCNA) analysis indicated that TYMS amplification was linked to poor prognosis and enriched in the folate metabolism pathways. Drug sensitivity analysis demonstrated that high TYMS expression positively correlated with sensitivity to Afatinib and Gefitinib, but negatively correlated with Methotrexate and Vorinostat. In conclusion, TYMS is upregulated in LUAD and may serve as an independent prognostic biomarker and therapeutic target.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory Medicine Center, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong, People's Republic of China.
- Key Laboratory of Antibody Engineering of Guangdong Higher Education Institutes, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, Guangdong, People's Republic of China.
- Medical Laboratory Center, Foresea Life Insurance Guangzhou General Hospital, Guangzhou, Guangdong, People's Republic of China.
- Department of Clinical Laboratory, The Fourth Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, People's Republic of China.
- Clinical Medical Laboratory Center, The Affiliated Traditional Chinese Medicine Hospital, Guangzhou Medical University, Guangzhou, Guangdong, China.
ORCID-Profile: Tiancai Liu, Tao Zeng
Förderung
- Guangdong Basic and Applied Basic Research Foundation
- Start-up Fund for High-level Talents in Affiliated Hospital of Guangdong Medical University
- Medical Science and Technology Research Project of Guangdong Province
- Discipline construction project of Guangdong Medical University
- National Natural Science Foundation of China
- Natural Science Foundation of Guangdong Province
- Basic and Applied Basic Research Foundation of Guangdong Province
Zitieren
APA
Shi, H., Zhang, P., Chen, J., Li, H., Zhang, X., Zeng, B., Liu, T., & Zeng, T. (2026). Multi‐Omics Analysis of TYMS as a Prognostic Biomarker and Therapeutic Target for Lung Adenocarcinoma. Cancer Medicine, 15(4). https://doi.org/10.1002/cam4.71814
Vancouver
Shi H, Zhang P, Chen J, Li H, Zhang X, Zeng B, et al. Multi‐Omics Analysis of TYMS as a Prognostic Biomarker and Therapeutic Target for Lung Adenocarcinoma. Cancer Medicine. 2026;15(4). doi:10.1002/cam4.71814
BibTeX
@article{Shi2026,
author = {Shi, Hansen and Zhang, Peijun and Chen, Jiayi and Li, Hua and Zhang, Xiaohuai and Zeng, Biyun and Liu, Tiancai and Zeng, Tao},
title = {Multi‐Omics Analysis of TYMS as a Prognostic Biomarker and Therapeutic Target for Lung Adenocarcinoma},
journal = {Cancer Medicine},
year = {2026},
volume = {15},
number = {4},
doi = {10.1002/cam4.71814}
}
EUVIMED